Neurology News: Breaking Neurology News, Comments and Articles.

Pilocytic astrocytomas of the optic nerve and their relation to pilocytic astrocytomas elsewhere in the central nervous system

Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans

AnatomyOne 2.0 includes four new personalized learning plans for Anatomy instructors and students. Salt Lake City, Utah (PRWEB) May 24, 2013 Amirsys today announces the release of AnatomyOne 2.0, with exciting new enhancements for instructors and students. Instructors can use the new features to help students stay more focused through personalize learning plan templates, targeted reading assignme...

Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Deutsche Bank 38th Annual Health Care Conference on Thursday, May 30, at 12:00 p.m. Eastern Standard Time. The conference will be held in Boston, MA. Individuals may listen to the live or an archived presentation made at the conference, which will be poste...

FDA panel backs Merck insomnia drug, but cites safety concerns

The US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee has recommended Merck’s insomnia drug suvorexant when given in low dosages, [...]

HackensackUMC at Pascack Valley Holds Ribbon-Cutting Ceremony to Officially Introduce New State-of-the-Art Community Hospital

WESTWOOD, N.J., May 24, 2013 /PRNewswire-USNewswire/ -- On Thursday, May 23 at HackensackUMC at Pascack Valley, Hackensack University Health Network and LHP Hospital Group officials, as well as state dignitaries, gathered to officially introduce the return of healthcare to the Pascack and Northern Valley communities. HackensackUMC at Pascack Valley will be the recipient of the first license N...

Acadia: Multiple Data Points Suggest Further Upside In The Stock

ByJosh Hutheson:Acadia Pharmaceuticals (ACAD) has to be one of the top performing stocks over the past year with a chart looking like this. The stock is now trading at about $14 a share which is 10 times higher than it was trading at one year ago. The run has been explosive, led by two news announcements, one in late-November and one in mid-April, that have served as big catalysts for the shares....

National Heat Awaress Day Raises Concerns for Pets Veterinarians warn of the danger of warm weather for pets

CHICAGO, May 24, 2013 /PRNewswire-iReach/ -- CHICAGO, ILL., MAY 24, 2013 . . . In recognition of National Heat Awareness Day, the veterinarians at Chicago Veterinary Emergency and Specialty Center (CVESC) (www.ChicagoVeterinaryEmergency.com), located at 3123 N. Clybourn, Chicago, remind pet owners to take precautions with their animals during the warm summer days. Among the more than 11,000 dogs a...

Study could open up new possibilities for early diagnosis of motor disorders

The scientists report these findings in the current online edition of "The Lancet Neurology". This pan-European study could open up new possibilities of early diagnosis and smooth the way for treatments which tackle diseases before the patient's nerv...

It Takes A Global Village to End MS

NEW YORK, May 24, 2013 /PRNewswire-USNewswire/ -- Multiple sclerosis is a life altering disease that affects each person in a unique and different way.   More than 2.1 million people worldwide live with MS, which is why demonstrating the power and importance of the global MS movement is critical on World MS Day -- May 29. (Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO)...

Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland

WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM).  Vanda was honored at the TCM's 25th Annual Tech Awards Celebration held in Bethesda, Maryland.  The Tech Awards Celebration recognizes the leaders and innovators in the...

Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 38th Annual dbAccess Health Care Conference on Wednesday, May 29, 2013, at 8:40 a.m. EDT (1:40 p.m. BST) from The Westin Boston Waterfront Hotel. The presentation may be accessed under the Investors tab on www.alkermes.com and will b...

Antibiotics: A new understanding of sulfonamide nervous system side effects

Since the discovery of Prontosil in 1932, sulfonamide antibiotics have been used to combat a wide spectrum of bacterial infections, from acne to chlamydia and pneumonia. However, their side effects can include serious neurological problems like nause...

Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity(TM) Renal Denervation System for Treatment-Resistant Hypertension

Milestone Marks a Critical Step Forward in Bringing Renal Denervation to Patients in the U.S. MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT), today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity(TM) renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter...

Groundbreaking 3D-Printed Device Saves Baby's Life

[WATCH VIDEO: Saving A Baby's Life With 3D Printed Device] Brett Smith for redOrbit.com - Your Universe Online Using 3D printing technology and a little ingenuity, doctors at the University of Michigan’s C.S. Mott Children's Hospital were able to help an infant with a collapsed bronchus to breathe by constructing a life-saving device. "Quite a few doctors said he had a good chance of not leav...

FDA panel recommends Merck’s insomnia drug for approval

An FDA advisory panel has voted in favour of Merck & Co's experimental insomnia drug, saying that it is safe and effective for elderly patients at the lower of two doses studied. While the FDA doesn't have to follow its committee's decision when...

US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses

The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee yesterday voted 13 to three to approve drug giant Merck & Co's (NYSE: MRK) investigational insomnia medicine suvorexant at doses of 15mg and 20mg, bu...

Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease

SEATTLE, May 23, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases tha...

FPMG Releases Advice on Playing to Win—Not Playing It Safe

A recent article on Forbes.com touched on three signs that might signal a person is in a dead-end job, a situation that performance management firm FPMG equates with failing to “play to win,” but playing it safe instead. Denise Federer, Ph.D., FPMG’s founder, notes that like sports teams, individuals can choose to either really go for it or take a more conservative approach. Tampa, FL (PRWEB...

Merck releases statement on FDA's Advisory Committee meeting about suvorexant

Merck, known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration about suvorex...

Anxious men fare worse during job interviews, study finds

(University of Guelph) Nervous about that upcoming job interview? You might want to take steps to reduce your jitters, especially if you are a man. People who are anxious perform more poorly in job interviews, and the effect is worse for men than wom...

Merck Statement on FDA Advisory Committee Meeting for Suvorexant

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck’s investigational medicine to treat insomnia. “We are excited abou...

Synageva BioPharma™ to Present at the Jefferies 2013 Global Healthcare Conference

Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that Sanj K. Patel, President and Chief Executive Officer of Synageva, will present at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 9:30 a.m. EST. The presentation wil...

Panel backs Merck's suvorexant

FDA's Peripheral and Central Nervous System Drugs Advisory Committee recommended approval of once-daily suvorexant from Merck & Co. Inc. (NYSE:MRK) to treat insomnia. The panel concluded suvorexant is an effective sleep aid but suggested it should be...

Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in Proof-of-Concept Clinical Trial

Data, published in Frontiers in Neurology, will be presented at the Alzheimer’s Association International Conference (AAIC) in Boston “This simple eye test has the potential to transform the way Alzheimer’s disease is detected and managed.” Carl Sadowsky, MD, FAAN, Medical Director Premiere Research Institute, West Palm Beach, Fla. Cog...

Economic Cost Of Strokes To Double In Coming Years

Brett Smith for redOrbit.com - Your Universe Online According to the American Heart Association (AHA), the number of strokes in the US is expected to increase dramatically over the next 17 years, and the costs associated with this increase will more than double. With a large portion of the US population about to enter a higher-risk age bracket, the shifting demographics could translate into a...